HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Endo, S. Articles by Sohara, Y. Search for Related Content PubMed PubMed Citation Articles by Endo, S. Articles by Sohara, Y. Related Collections Mediastinum

Ann Thorac Surg 2004;77:1745-1750
© 2004 The Society of Thoracic Surgeons

---

Original article: general thoracic

Experience with programmed steroid treatment with thymectomy in nonthymomatous myasthenia gravis

^a Division of General Thoracic Surgery, Department of Surgery, Jichi Medical School, Tochigi, Japan

Accepted for publication October 16, 2003.

^* Address reprint requests to Dr Endo, Division of General Thoracic Surgery, Department of Surgery, Jichi Medical School, Minamikawachi-machi, Kawachi-gun, Tochigi 329-0498, Japan.
e-mail: tcvshun{at}jichi.ac.jp

BACKGROUND: The benefit of thymectomy in myasthenia gravis management is recognized but the perioperative course can fluctuate. The goal of this study was to assess the feasibility and clinical benefit of dose-escalated steroid therapy with thymectomy for nonthymomatous myasthenia gravis.

METHODS: We reviewed the records of 69 myasthenia gravis patients who were followed up after undergoing transsternal thymectomy with extended anterior mediastinal dissection in our hospital between 1976–2000. Forty-eight patients in the programmed treatment group who had dose-escalated and de-escalated steroid therapy during the perioperative period comprised 17 patients with ocular myasthenia gravis and 31 patients with generalized myasthenia gravis. Clinical benefits and clinical remission, which was diagnosed when the patients were symptom-free without medications for at least 1 year, were compared with those of 21 patients in the occasional treatment group who received medications occasionally over the perioperative period.

RESULTS: Postoperative respiratory failure and myasthenic crisis did not occur in the programmed treatment group but did occur in 6 patients in the occasional treatment group. Remission rates in the programmed treatment group (mean follow-up, 6.4 years) were 30% at 3 years, 38% at 5 years, and 46% at 10 years; rates in the occasional treatment group (mean follow-up, 9.6 years) were 25% at 3 years, 25% at 5 years, and 45% at 10 years.

CONCLUSIONS: Programmed steroid therapy in patients with nonthymomatous myasthenia gravis is feasible and it provides clinical benefit when fluctuating symptoms occur during the perioperative period.

This article has been cited by other articles:

				M. Kanzaki, T. Obara, S. Sasano, and T. Onuki Is taking preoperative high-dose steroid necessary? Eur. J. Cardiothorac. Surg., October 1, 2006; 30(4): 688 - 689. [Full Text] [PDF]

				M. Zielinski and J. Kuzdzal Preoperative use of steroids in patients with myasthenia gravis. Ann. Thorac. Surg., May 1, 2006; 81(5): 1946 - 1946. [Full Text] [PDF]

				S. Endo Reply. Ann. Thorac. Surg., May 1, 2006; 81(5): 1946 - 1947. [Full Text] [PDF]

				W. Fang, W. Chen, G. Chen, and Y. Jiang Surgical Management of Thymic Epithelial Tumors: A Retrospective Review of 204 Cases Ann. Thorac. Surg., December 1, 2005; 80(6): 2002 - 2007. [Abstract] [Full Text] [PDF]